SustainabilityESG Data

Environmental

INPUT

Items Units FY2018 FY2019 FY2020 FY2021 FY2022
Energy consumption
Electricity Thousand kwh 95,124 92,077 88,772 90,196 115,969
(of which) In-house power generation Thousand kwh 2,942 3,175 2,278 2,239 1,465
(of which) Solar power Thousand kwh - - - 96 285
Kerosene kl 1,894 1,893 1,970 1,991 1,728
Heavy oil (A type) kl 874 942 761 736 511
Light oil kl 0.09 0 0 0.09 0
LPG t 9 5 4 1 2,187
City gas Thousand m3 4,070 3,981 3,817 3,984 4,966
Industrial steam GJ 82,779 64,870 65,146 56,700 55,484
Crude oil equivalent kl 32,336 31,015 30,130 30,452 40,629
Water
Amount of water used (clean water and industrial water used) Thousand m3 438 405 367 360 357
Basic unitAmount of water used divided by production volume (unit: hundred million tablets) - 2.2 1.7 1.6 1.4 1.2
(of which) clean water Thousand m3 395 368 330 325 307
(of which) industrial water Thousand m3 43 36 37 35 50

* Sawai Pharmaceutical only (before FY2020)
* Including even Kaken Shouyaku's data except water (from FY2021 onward)
* Including even Trust Pharmatech's data except water (from FY2022 onward)

OUTPUT

Items Units FY2018 FY2019 FY2020 FY2021 FY2022
Water
Total drainage volume Thousand m3 402 390 360 353 330
(of which) sewer drainage Thousand m3 307 143 152 165 142
(of which) river drainage Thousand m3 38 50 48 39 37
(of which) Others Thousand m3 56 197 160 149 151
CO2
CO2 emission kt-CO2 60.3 53.1 50.5 53.3 69.3
Basic unitEmission volume divided by production volume (unit: billion tablets) - 3.1 2.2 2.1 2.0 2.4
(of which) Scope1 CO2 emission kt-CO2 15.5 15.5 14.8 15.2 22.7
(of which) Scope2 CO2 emission kt-CO2 44.8 37.6 35.6 38.1 46.5
Scope3 CO2 emission
Total Scope3 emissions in the value chains kt-CO2 174.2 196.4 194.6 222.5 256.6
1. Purchased goods and services kt-CO2 141.0 165.2 156.8 188.9 198.7
2. Capital goods kt-CO2 14.6 10.4 17.6 12.2 36.0
3. Fuel-and energy-related activities (not included in scope 1 or scope 2) kt-CO2 4.4 8.2 8.0 7.8 8.1
4. Upstream transportation and distribution kt-CO2 N/A N/A N/A N/A N/A
5. Waste generated in operations kt-CO2 1.2 0.9 0.9 1.0 1.1
6. Business travel kt-CO2 0.4 0.4 0.2 0.2 0.2
7. Employee commuting kt-CO2 0.7 1.0 0.9 0.9 1.1
8. Upstream leased assets kt-CO2 N/A N/A N/A N/A N/A
9. Downstream transportation and distribution kt-CO2 11.3 9.9 9.8 10.7 10.3
10. Processing of sold products kt-CO2 N/A N/A N/A N/A N/A
11. Use of sold products kt-CO2 N/A N/A N/A N/A N/A
12. End-of-life treatment of sold products kt-CO2 N/A N/A N/A N/A N/A
13. Downstream leased assets kt-CO2 N/A N/A N/A N/A N/A
14. Franchises kt-CO2 N/A N/A N/A N/A N/A
15. Investments kt-CO2 0.5 0.5 0.5 0.8 1.1
Waste
Amount of waste, etc. t 1,784 2,095 1,981 2,094 2,285
Basic unitDischarge amount divided by production volume (unit: hundred million tablets) - 9.0 8.9 8.4 7.9 7.9
Recycled volume t 851 1,132 946 1,363 1,508
Recycling rate % 48 54 48 65 66
Chemical substances, etc.
Amount of release and transfer of specified chemical substancesSubjects: acetonitrile and methylene chloride (dichloromethane) t 26 29 27 31 32
NOx t 20 21 18 20 5
SOx t 1 2 1 1 1

* Sawai Pharmaceutical only (before FY2020)
* Including even Kaken Shouyaku's data except water and Scope3 CO2 emission (from FY2021 onward)
* Including even Trust Pharmatech's data except water and Scope3 CO2 emission (from FY2022 onward)

Social

Status of Employees

Items Units FY2018 FY2019 FY2020 FY2021 FY2022
Number of Employees Persons 3,131 3,066 3,003 2,968 3,393
Japan Persons 2,568 2,491 2,444 2,474 2,944
US Persons 563 575 559 494 449
Average number of temporary employees Persons 438 366 327 330 346
Japan Persons 386 333 298 310 328
US Persons 51 33 29 20 18
Number of Employees*1 Persons 2,568 2,491 2,444 2,474 2,944
Manufacturing Persons 1,687 1,644 1,607 1,636 2,015
R&D Persons 257 251 246 253 295
Administration, Sales Persons 624 596 591 585 634
Male Persons 1,740 1,672 1,642 1,663 1,920
Female Persons 828 819 802 811 1,024
Male (Ratio) % 67.8 67.1 67.2 67.2 65.2
Female (Ratio) % 32.2 32.9 32.8 32.8 34.8
Number of employees in managerial positions*1 Persons 250 247 258 256 262
Number of MRs*2 Persons 436 394 382 379 375
Number of persons with pharmacist qualifications*3 Persons 268 261 256 255 246
Mean age*4 Age 37.2 38.0 38.6 38.8 38.2
Male Age 37.1 37.9 38.7 38.6 38.2
Female Age 37.3 38.1 38.6 39.0 38.0
Average length of service*4 Years 7.3 8.2 8.9 9.3 8.9
Male Years 7.4 8.3 9.1 9.5 9.2
Female Years 7.0 7.8 8.5 8.8 8.3
Number of recruits*4 Persons 141 69 76 166 201
Hiring of new graduates Persons 73 11 10 49 83
(of which) Male Persons 42 3 5 33 44
(of which) Female Persons 31 8 5 16 39
New employees transferred from other company, etc. Persons 29 58 66 117 118
(of which) Male Persons 20 30 28 79 82
(of which) Female Persons 9 28 38 38 36
Employee turnover*4 % 5.6 5.7 2.8 3.3 3.1
Retention of new graduates (at the time after 3years of employment)*4 % 95.2 94.6 94.7 92.9 93.7
Salary and benefit*5 Million yen 5,303 5,161 5,132 661 722
Ratio of employees covered by the collective agreements*1 % 90.3 90.1 89.4 89.7 91.1
Unionization rate (Sawai Pharmaceutical Workers Union)*1 % 75.5 75.9 77.1 80.5 85.1

*1 Sawai Pharmaceutical, Medisa Shinyaku and Kaken Shoyaku, Trust Pharmatec (from FY2022 onward)
*2 Sawai Pharmaceutical and Kaken Shoyaku
*3 Sawai Pharmaceutical, Trust Pharmatec (from FY2022 onward)
*4 Sawai Pharmaceutical
*5 Sawai Pharmaceutical (before FY2020), Sawai Group Holdings (from FY2021 onward)

Diversity Promotion*1

Items Units FY2018 FY2019 FY2020 FY2021 FY2022
Number of foreign national employees Persons 8 7 6 7 7
Number of female employees in managerial positions Persons 15 15 15 17 18
Ratio of female employees in managerial positions*2 % 6.0 6.1 5.8 6.6 6.9
Ratio of disabled employees*3 % 1.80 1.78 2.48 2.38 2.57
Number of employees rehired after retirement Persons - 43 43 59 78
Percentage of rehired employees who retired at retirement age % - 88.2 95.2 87.5 96.4
Percentage of mid-career employees in managerial positions % 61 60 56 61 63

*1 Sawai Pharmaceutical only
*2 Target ratio of female employees in managerial positions: 8% and above by the end of March 2024.
*3 Target: To maintain the level over the statutory employment ratio of disabled employees. The statutory employment ratio for disabled employees since March 2021 is 2.3%. The figures are as of June 1 of the following year.

Work Environment*1

Items Units FY2018 FY2019 FY2020 FY2021 FY2022
Paid leave utilization rate*2 % 74.6 75.0 72.9 71.1 80.5
Number of employees who take child-care leave Persons - 74 74 42 49
(of which) Male Persons - - - 10 20
(of which) Female Persons - - - 32 29
Child-care leave utilization rate*3 % - 2.7 2.7 34.7 50.0
Return rate from child-care leave % 92.0 96.9 91.7 100 100
Number of employees who take family-care leave Persons 0 4 3 0 1
Average hours of overtime work per month*4 Hours - - 16.5 17.7 15.8
Stress check examination rate % - - - 97.6 97.8
Medical checkup rate % - - - 100 100
Smokers rate % - 14.2 13.7 12.8 12.7
Frequency rate of occupational injuries % 0 0.87 0 0 0.96

*1 Sawai Pharmaceutical only
*2 Eligible Persons: Union members, Terms: From 1st Jan. to 31st Dec.
*3 (FY2020 and before) Denominator is the number of employees as of the end of March. (FY2021 and after) Denominator is the number of employees who gave birth to children by themselves or their spouses among Sawai-registered or transferred employees to Sawai.
*4 Including employees transferred from Sawai Pharmaceutical to Sawai Group companies.

Employee Growth

Items Units FY2018 FY2019 FY2020 FY2021 FY2022
Number of employee-training*1 Times 22 16 - - -
Number of employees trained*2 Persons 654 600 4,038 2,840 4,034
Employee training expenses*3 Million yen 87 62 45 63 85
Pass rate of MR certification test*3 % 100 is not applicable is not applicable is not applicable 100

*1 Sawai Pharmaceutical. Not counted since FY2020 due to diversification of training methods and contents.
*2 Sawai Pharmaceutical. From FY2020 the number of participants in e-learning, etc. is included.
*3 Sawai Pharmaceutical, Medisa Shinyaku and Kaken Shoyaku

Products / Stable Supply

Items Units FY2018 FY2019 FY2020 FY2021 FY2022
Number of products*1 Items 740 740 780 790 790
Number of new products launched*2 - 14 generic drugs with 33 strengths 5 generic drugs with 12 strengths 19 generic drugs with 44 strengths 13 generic drugs with 32 strengths 11 generic drugs with 23 strengths
No. of tablets sold*2 Billion tablets 11.9 12.4 13.3 14.8 15.0
Number of patents owned*2 Items 31 36 37 42 45
Number of patents pending*2 Cases 34 31 38 44 32
Number of raw material supplier audits*3 Times 193 188 120 168 212
Number of inquiries to drug information center*2 Cases 44,800 46,800 48,600 49,800 46,700
Number of out of stock products*2 Items 6 4 8 16 6
Product recall (Class Ⅰ)*3 Cases 0 1 0 0 0
Product recall (Class Ⅱ)*3 Cases 5 1 7 8 5
Product recall (Class Ⅲ)*3 Cases 0 0 0 0 0

*1 Sawai Pharmaceutical (The figures are as of April 1 of the following year)
*2 Sawai Pharmaceutical
*3 Sawai Pharmaceutical (before FY2020), Sawai Group in Japan (from FY2021 onward)

Promotion of Communication

Items Units FY2018 FY2019 FY2020 FY2021 FY2022
Dialogue with institutional investors and analysts*1 Times 157 124 129 141 154
Communication with Mass Media*2 Times 37 38 28 42 59
Factory tours Times 166 164 16 12 45
Expenditures for social contribution activities Million yen 76 76 51 212 220

*1 Total
*2 Interview, brief session, etc.

Medical cost-saving impact

Items Units FY2018 FY2019 FY2020 FY2021 FY2022
Medical cost-saving impact (Japan) Billion yen 273.4 296.7 317.6 338.2 280.9

Governance

Items Units FY2018 FY2019 FY2020 FY2021 FY2022
Number of directors (board members) Persons 8 7 6 6 6
Number of external directors Persons 2 2 2 2 2
Ratio of external directors % 25.0 28.6 33.3 33.3 33.3
Number of female directors Persons 1 1 1 1 1
Ratio of female directors % 12.5 14.3 16.7 16.7 16.7
Number of Audit & Supervisory Board members Persons 4 4 3 3 3
Number of external Audit & Supervisory Board members Persons 2 2 2 2 2
Ratio of external Audit & Supervisory Board members % 50.0 50.0 66.7 66.7 66.7
Number of corporate officers Persons 11 10 12 8 11
(of which) Number of female corporate officers Persons 1 1 1 0 1
Number of board meetings Times 16 16 16 13 13
Number of attendances of external directors
Nawomi Todo Attendance/Total
%		 15/16
93.8%		 16/16
100%		 16/16
100%		 13/13
100%		 13/13
100%
Masatoshi Ohara Attendance/Total
%		 - 12/13
92.3%		 16/16
100%		 13/13
100%		 13/13
100%
Number of attendances of external Audit & Supervisory Board members
Takanobu Tomohiro Attendance/Total
%		 16/16
100%		 15/16
93.8%		 14/16
87.5%		 13/13
100%		 13/13
100%
Junichi Hirano Attendance/Total
%		 16/16
100%		 16/16
100%		 15/16
93.8%		 13/13
100%		 13/13
100%
Number of Audit & Supervisory Board meetings Times 15 19 18 16 13
Number of attendances of external Audit & Supervisory Board members
Takanobu Tomohiro Attendance/Total
%		 15/15
100%		 18/19
94.7%		 16/18
88.9%		 16/16
100%		 13/13
100%
Junichi Hirano Attendance/Total
%		 15/15
100%		 19/19
100%		 17/18
94.4%		 16/16
100%		 13/13
100%
Number of matters to be resolved at the board meeting Cases 129 100 106 77 71
Number of matters to be reported at the board meeting Cases 156 150 92 62 53
Total compensation allocation for directors (board members) and Audit & Supervisory Board members
Number of eligible directors (excluding external directors) Persons 7 6 5 4 4
Total compensation allocation Million yen 348 399 299 177 292
(of which) Fixed compensation Million yen 266 244 205 177 153
(of which) Stock options Million yen 16 40 24 - 84
(of which) Performance-based compensation Million yen 66 81 70 - 55
(of which) Retirement benefits Million yen - 34 - - -
Number of eligible Audit & Supervisory Board members (excluding external Audit & Supervisory Board members) Persons 3 2 2 1 1
Total compensation Million yen 24 22 18 17 17
(of which) Fixed compensation Million yen 24 22 18 17 17
Number of eligible exernal directors and external Audit & Supervisory Board members Persons 4 5 4 4 4
Total compensation, etc. Million yen 23 24 25 28 30
(of which) Fixed compensation Million yen 23 24 25 28 30
Number of days between the dates of dispatch of the convocation notice and annual shareholder’s meeting Days 17 18 18 (Jun.)
17 (Dec.)		 Meeting not held due to the
transformation
into a holding company		 17
Number of cases of whistle-blowing (including consultation) or whistle blowers (Japan) Cases 1 14 8 7 6
Exclusion recommended by the Fair Trade Commission, etc. (Japan) Cases 0 0 0 0 0
Shut down or suspension of business caused by scandal or misconduct (Japan) Cases 0 0 0 0 0
Criminal indictments for accidents or incidents related to compliance violations (Japan) Cases 0 0 0 0 0
Detection by price cartel (Outside Japan) Cases 0 0 0 0 0
Detection by bribery (Outside Japan) Cases 0 0 0 0 0
Detection by other reasons (Outside Japan) Cases 0 0 0 0 0

* Data on Board and Audit & Supervisory Board is for Sawai Pharmaceutical (before FY2020), for Sawai Group Holdings (from FY2021 onward)

Back to Sustainability Top